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Abstract
We recently showed that patients with primary Sj€ogren Syndrome (pSS) have significantly higher bone mineral density (BMD) com-
pared to healthy controls. The majority of those patients (69%) was using hydroxychloroquine (HCQ), which may have favourable
effects on BMD. To study the direct effects of HCQ on human MSC-derived osteoblast activity. Osteoblasts were cultured from human
mesenchymal stromal cells (hMSCs). Cultures were treated with different HCQ doses (control, 1 and 5 µg/ml). Alkaline phosphatase
activity and calcium measurements were performed to evaluate osteoblast differentiation and activity, respectively. Detailed microarray
analysis was performed in 5 µg/ml HCQ-treated cells and controls followed by qPCR validation. Additional cultures were performed
using the cholesterol synthesis inhibitor simvastatin (SIM) to evaluate a potential mechanism of action. We showed that HCQ inhibits
both MSC-derived osteoblast differentiation and mineralization in vitro. Microarray analysis and additional PCR validation revealed a
highly significant up-regulation of the cholesterol biosynthesis, lysosomal and extracellular matrix pathways in the 5 µg/ml HCQ-treated
cells compared to controls. Besides, we demonstrated that 1 µM SIM also decreases MSC-derived osteoblast differentiation and miner-
alization compared to controls. It appears that the positive effect of HCQ on BMD cannot be explained by a stimulating effect on the
MSC-derived osteoblast. The discrepancy between high BMD and decreased MSC-derived osteoblast function due to HCQ treatment
might be caused by systemic factors that stimulate bone formation and/or local factors that reduce bone resorption, which is lacking
in cell cultures.
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Key messages
• HCQ treatment leads to decreased MSC-derived osteoblast
differentiation and mineralization in vitro
• HCQ significantly up-regulates the cholesterol metabolism
pathway and lysosomal pathway, which may lead to the
observed phenotype
• HCQ disturbs cell-surface attachment of MSC-derived and the
extracellular matrix composition they produce
• Contrary to expected, SIM treatment also significantly
decreased MSC-derived osteoblast differentiation and mineral-
ization
Introduction
Hydroxychloroquine (HCQ) is an antimalarial agent now often used in
systemic autoimmune diseases such as pSS, rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE) due to its anti-inflammatory
properties [1–3]. The pharmacokinetics of HCQ has been described
extensively, but the exact mechanism of action remains unclear [4].
In addition to its anti-inflammatory effects, the literature concern-
ing the pharmacodynamics of HCQ is extensive. In vivo studies
showed that HCQ has beneficial effects on the lipid profile of patients
with RA and pSS by lowering serum levels of low-density lipoprotein
(LDL) cholesterol, triglycerides and total cholesterol as well as
increasing high-density lipoprotein (HDL) cholesterol [5, 6]. Addition-
ally, HCQ has been associated with beneficial cardiovascular and anti-
cancer effects, but it is not used for these conditions as there are
better alternatives available [7, 8].
In vitro studies have shown that HCQ is capable of inhibiting Toll-
like receptors (TLR) 7 and 9, which are involved in the pathogenesis
of SLE [9–11]. Although Raicevic et al. reported that osteoblasts do
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not express TLR 7 and 9, other studies did show TLR 9 expression in
osteoblasts [12–14]. HCQ has also been identified as an autophagy
inhibitor by blocking the degradation of autophagosomes and pro-
moting apoptosis in endometriosis, cervical cancer cells and myeloid
leukaemia [15–17]. In addition to the effects on autophagosomes,
HCQ also acts on lysosomes. Some studies reported an increased
lysosomal pH by HCQ treatment, which is associated with decreased
lysosomal function [18, 19], while other studies did not observe a sig-
nificant difference in lysosomal pH [10, 11]. Furthermore, HCQ has
been associated with increased lysosomal membrane permeabiliza-
tion (LMP), a process occurring prior to mitochondrial membrane
permeabilization (MMP) leading to apoptosis [20].
We recently reported that patients with pSS, of which the majority
was using HCQ, had a higher BMD compared to healthy controls [21].
Additionally, we found two studies showing a positive association
between BMD and HCQ use in SLE patients, which was corrected for
patient characteristics and disease activity [22, 23], while one study
reported a negative effect of HCQ on BMD [24]. We recently showed
that HCQ leads to decreased osteoclast differentiation and activity due
to HCQ treatment [25]. Based on our previous studies, we have been
suggested that HCQ stimulates the activity of the bone forming cells,
the osteoblasts, which has not been studied before.
Materials and methods
Cell cultures
Human mesenchymal stromal cells (hMSCs; Lonza, Basel, Switzerland)
were differentiated into osteoblasts as described before [26]. Briefly,
hMSCs were differentiated into mineralizing osteoblasts within 2–
3 weeks, using dexamethasone and b-glycerophosphate. The media were
refreshed twice a week, and cells were treated without (control) and with
HCQ (1 or 5 lg/ml). Alkaline phosphatase (ALP) activity was measured at
day 7 of culture. Osteoblast mineralization was analysed by measuring the
amount of precipitated calcium corrected for total protein at day 18 as
extensively described before [26]. Images were taken during culture to
evaluate cell morphology. For microarray analysis, osteoblast cultures
with and without 5 lg/ml HCQ were stopped at day 5.
Mineralization staining assays
Calcium depositions were visualized with the Alizarin red staining assay
as described before [26]. Briefly, cells were fixed with 70% (vol/vol)
ethanol and, after washing, stained for 10–20 min. with alizarin Red S
solution. Phosphate depositions were visualized with the von Kossa
staining assay as described before [26]. Cells were washed with water,
and the wells were stained for 30 min. with 5% silver nitrate (in bright
daylight), incubated for 1 min. in 5% sodium carbonate in 25% formalin
and finally for 2 min. in 5% sodium thiosulphate.
Activation of simvastatin
hMSCs were differentiated to osteoblasts as described before. In addi-
tion, cells were treated with a dose range from 100 to 100 lM
simvastatin (SIM; Sigma-Aldrich, The Netherlands) with and without
5 lg/ml HCQ to evaluate whether the effects of HCQ on both osteoblast
differentiation and mineralization could be antagonized by SIM. Simvas-
tatin was activated before use as previously described [27]. Briefly,
5 mg simvastatin was dissolved in 125 ll of 100% ethanol, with subse-
quent addition of 187.5 ll of 0.1 N NaOH. The solution was heated to
50°C for 2 hrs in a water bath and then activated by neutralizing to pH
7.0 using 0.1 N HCl. The resulting solution was brought to a final con-
centration of 4 mg/ml using distilled water, and aliquots were stored at
4°C until use.
Immunocytochemistry assays
hMSCs were cultured for 5 days and stained for cytoskeletal actin.
Briefly, cells were washed with phosphate buffer solution (PBS) and
fixed with 10% formalin. PBS + Triton X-100 was added for 10 min.,
followed by blocking aspecific binding sites, using PBS + Tween 0.05%
+ BSA 1% for 30 min. Cells were then incubated with a rhodamine-con-
jugated phalloidin antibody for 1 hr at room temperature and washed
with PBS + Tween 0.05% followed by DAPI staining. Staining of the
cytoskeleton was visualized under a fluorescent microscope using a
535 nm filter. Additionally, a DAPI filter (365 nm) was used to visualize
the nuclei and evaluate any apoptotic events (e.g. nuclear fragmentation,
chromatin condensation).
For visualization and quantification of focal adhesions, cells were
labelled for 1 hr with rabbit monoclonal anti-vinculin antibody at 1:200
dilution at RT, followed by secondary Alexa Fluor 488 goat anti-rabbit
IgG at 1:400 dilution for a total of 1 hr [28].
Illumina gene chip-based gene expression
Total RNA of hMSCs was isolated as described before [26]. Illumina
Human HT-12 v4 BeadChip (Illumina, Inc, San Diego, CA, USA) human
whole-genome expression arrays were used. RNA integrity of isolated
RNA was assessed by RNA 6000 Nano assay on a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). The RNA of 3 biologic
replicates for each condition (control, 1 and 5 lg/ml HCQ) was anal-
ysed. The Illumina TotalPrep RNA Amplification Kit (Ambion, Austin,
TX, USA) was used for RNA amplification of each sample according to
manufacturer’s instructions. In short, T7 oligo(dT) primer was used to
generate single-stranded cDNA, followed by a second-strand synthesis
to generate double-stranded cDNA. In vitro transcription was per-
formed to synthesize biotin-labelled cRNA using T7 RNA polymerase.
The cRNA was column purified and checked for quality by RNA 6000
Nano assay. A total of 750 ng of cRNA was hybridized for each array
using the standard Illumina protocol, with streptavidin-Cy3 (GE Health-
care, Piscataway, NJ, USA) being used for detection. Slides were
scanned on an iScan and analysed using GenomeStudio (both from
Illumina, Inc.).
Microarray analysis
Background was subtracted from the raw data using GenomeStu-
dioV2010.1 (Gene Expression Module 1.6.0, Illumina), and data were
processed using the Bioconductor R3.3 lumipackage (www.biocond
uctor.org) [29]. The data were transformed by variance stabilization and
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quantile normalization. Probes that were detected at least three times in
the experiments (Illumina detection P-value < 0.01) were considered to
be expressed and were further analysed. Differentially expressed probes
were identified using Bioconductor Package Limma (www.bioconductor.
org), with adjusted P-values adjusted to reduce the false discovery rate
(FDR; P < 0.01) [30]. Gene ontology (GO) analysis, selected Illumina
IDs were analysed using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) 2008 hosted by the National Institute of
Allergy and Infectious Diseases (NIAID) at the National Institutes of
Health (Bethesda, MD, USA) and at GeneMANIA (http://www.genemania.
org/). Merging of overlapping GO annotations was performed using the
Reduce and Visualize Gene Ontology (REVIGO) tool (www.revigo.irb.hr)
[31].
Quantitative real-time PCR analyses
The methods used for RNA extraction and cDNA synthesis and real-time
(RT)-PCR have been described previously [26]. Real-time qPCR was
performed using the ABI Prism 7900 sequence detection system
(Applied Biosystems, Thermo Fisher Science, Bleiswijk, The Nether-
lands), and the results were analysed using SDS version 2.3 software
(Applied Biosystems). Data are presented as relative mRNA levels calcu-
lated and corrected for gene expression of the housekeeping gene
GAPDH by the formula: 2D(Ct of gene of interestCt of housekeeping
gene). All primers used are summarized in Table 1.
Statistics
All results are expressed as means with standard error of the mean
(S.E.M.) Comparisons of the continuous variables between three groups
(control, 1 and 5 lg/ml HCQ) and two groups (control and 5 lg/ml
HCQ) were performed using the one-way analysis of variance (ANOVA)
and Student’s t-test, respectively. For ANOVA analysis, the least significant
difference post hoc test was used. A P-value < 0.05 was considered
significant. All analyses were performed in SPSS (version 21, IBM).
Results
HCQ inhibits osteoblast differentiation and
activity
Osteoblast differentiation, as measured by ALP activity at day 7, was
significantly decreased dose-dependently between HCQ doses of 1
and 5 lg/ml versus controls (1.54  0.11 mU/lg for HCQ dose
1 lg/ml and 0.8  0.044 mU/lg for HCQ dose 5 lg/ml versus
2.7  0.15 mU/lg for the controls, P < 0.001 for both and
P < 0.001 for the dose-dependent trend) (Fig. 1A). Mineralization at
day 18 was significantly decreased between 5 lg/ml HCQ and con-
trols (0.40  0.015 nmol/lg versus 9.75  1.76 nmol/lg,
P = 0.011 and P < 0.001 for the dose-dependent trend). In fact,
using the highest HCQ dose, mineralization was virtually absent at
18 days of culture (Fig. 1B). Additionally, using alizarin red and von
Kossa stainings, mineralization in the HCQ-treated cells was absent
compared to the controls (Fig. 1C). During culture, evaluation of the
cells showed an altered morphology in the 5 lg/ml HCQ-treated cells
compared to the controls at day 14 (Fig. 1D). We performed vinculin
stainings at day 5 of culture to analyse for differences in cell-surface
attachment between HCQ-treated cells and controls. HCQ-treated cells
showed significantly less staining compared to the controls indicating
less cell-surface attachment due to HCQ (Fig. 1E). Furthermore, there
is no evidence for a difference in apoptotic events between the condi-
tions (data not shown) or cytoskeletal malformations (actin) between
controls and HCQ-treated cells based on rhodamine-phalloidin
staining (Fig. 1E).
Table 1 Primer sequences of the analysed genes
Gene Forward primer Reverse primer
GAPDH CCGCATCTTCTTTTGCGTCG CCCAATACGACCAAATCCGTTG
TNC CACAGCCACGACAGAGGC AAAGGCATTCTCCGATGCCA
ALP TAAAGCAGGTCTTGGGGTGC GGGTCTTTCTCTTTCTCTGGCA
ACAT2 GAGCTTTGCCTAGCTTGCAG TGAAGGAACCTATGATGGTCCG
DHCR7 GAGGTGTGCGCAGGACTTTA CTTCTTGAACCGGCCCCTTA
CTSK TGCCCACACTTTGCTGCCGA GCAGCAGAACCTTGAGCCCCC
CTNS AACGCGGTGCATTCCTGA GCGTCTCCAAAGCAATCTGA
GPNMB TAAACCTTGAGTGCCTGCGT TGAAATCGTTTGGCGGCATC
HMGCR TCTAGTGAGATCTGGAGGATCCAA GGATGGGAGGCCACAAAGAG
GO, gene ontology; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; TNC, Tenascin C; ALP, Alkaline Phosphatase; ACAT2, Acetyl-CoA
Acetyltransferase 2; DHCR7, 7-Dehydrocholesterol Reductase; CTSK, Cathepsin K; CTNS, Cystinosin, Lysosomal Cystine Transporter; GPNMB,
Glycoprotein Nmb; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase.
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Microarray analysis of HCQ-treated hMSCs yields
4 regulated processes in MSC-derived
osteoblasts
To gain insight into processes regulated by HCQ during osteoblast
differentiation, we performed microarray gene expression analysis
using Illumina Human HT-12 v4 expression arrays. hMSCs were cul-
tured and treated without or with HCQ (1 or 5 lg/ml) for 5 days as
described above. Next, whole-genome analysis of mRNAs was
assessed following induction of osteogenic differentiation. When eval-
uating twofold up- and down-regulated genes in HCQ-treated cells
versus controls, a clear dose response between 1 lg/ml and 5 lg/ml
HCQ treatment was observed (Fig. 2A–B). In addition, none of the
genes was stronger regulated by 1 lg/ml HCQ compared to 5 lg/ml
HCQ. Therefore, we excluded the 1 lg/ml HCQ-treated cells from fur-
ther analysis. A total of 119 gene probes corresponding to 72 genes
were differentially expressed (q < 0.05 and twofold change) at day 5
compared to controls. GO analysis of these gene probes resulted in a
significant overrepresentation of 14 functional categories. Evaluation
of the regulated genes within the categories showed a large overlap
between the GO terms, and using REVIGO, we narrowed them down
based on the largest number of genes to four main processes, namely
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Fig. 1 Effect of HCQ on MSC-derived
osteoblast differentiation and mineraliza-
tion. All experiments are performed twice
with N = 4 for every condition. (A) ALP
measurement at day 7. (B) Mineralization
at day 18 (C) Alizarin red staining and von
Kossa staining in controls versus HCQ-
treated cells (D) Morphology of MSC-
derived osteoblasts at day 14 of culture in
controls versus 5 lg/ml HCQ-treated cells.
(E) DAPI/Actin/Vinculin staining in controls
versus 5 lg/ml HCQ-treated cells. Data
are presented as mean  S.E.M.
*P < 0.05, **P < 0.01. HCQ, hydroxy-
chloroquine; ALP, alkaline phosphatase.
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(i) lipid metabolic process (GO:000629), (ii) developmental process
(GO:0032502), (iii) lysosome (GO:0005764) and 4) extracellular
matrix (GO:0031012) (Table 2).
PCR validation of HCQ-regulated genes
underlying selected GO terms from microarray
analysis
From every GO term, we selected two genes of interest for PCR vali-
dation (Table 2). For the GO term ‘lipid metabolism’ process, we
selected acetyl-CoA acetyltransferase 2 (ACAT2) and 7-dehydrocho-
lesterol reductase (DHCR7), which encode the first and last enzyme
involved in the cholesterol biosynthesis pathway [32]. For the GO
term ‘extracellular matrix’, we selected tenascin C (TNC) and alkaline
phosphatase (ALP) as these genes were highly regulated by HCQ and
are known to be involved in osteoblast differentiation. Genes belong-
ing to the GO term ‘lysosome’ include cathepsin K (CTSK) (a cysteine
proteinase) and cystinosin, lysosomal cystine transporter (CTNS) (a
small lysosomal membrane protein). All selected genes were also
regulated in the GO term ‘developmental process’, and therefore, we
only selected glycoprotein Nmb (GPNMB) from this GO term, as this
was the strongest regulated gene upon HCQ treatment in our experi-
ment. We validated these seven genes using real-time PCR. Although
expression of two genes (ALP and TNC) did not reach significance
between controls and HCQ treatment, all genes showed the same
direction of regulation compared to our results from the microarray
analysis (Fig. 3A–G).
Simvastatin decreases osteoblast differentiation
and mineralization alone and in combination
with 5 lg/ml HCQ
As HCQ up-regulates the cholesterol synthesis pathway, we have
been suggested that SIM (a cholesterol synthesis inhibitor) would
antagonize the inhibitory effects of HCQ on osteoblast differentiation
and mineralization. Therefore, we treated MSCs with SIM in multiple
doses in the presence or absence of 5 lg/ml HCQ to evaluate the
effects of SIM alone and in combination with HCQ on MSC-derived
osteoblasts. We found that SIM doses of 100 and 10 nM were inef-
fective, while SIM doses above 1 lM increased cell death in the
early-phase of the culture probably due to its cellular toxicity (data
not shown).
We showed that 1 lM SIM significantly decreased osteoblast dif-
ferentiation, as measured by ALP activity, compared to untreated con-
trols (0.67  0.038 mU/lg for 1 lM SIM versus 1.9  0.33 mU/lg
for the controls, P < 0.001) (Fig. 4A). The effect of 1 lM SIM was
similar to the effect of HCQ only as well as to the combination of
these two drugs. Additionally, both 0.2 and 1 lM SIM significantly
decreased osteoblast mineralization compared to the controls
(1.49  0.072 nmol/lg for 0.2 lM SIM and 1.63  0.018 nmol/lg
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Table 2 GO term enrichment analysis of 5 lg/ml HCQ treatment versus control at day 5 of MSC-derived osteogenesis
GO Name Fold enrichment Number of genes P-value
Biological process
GO:0006629 Lipid metabolic process 4.1 20 0.0002
GO:0032502 Developmental process 2.0 37 0.014
Cellular component
GO:0005764 Lysosome 9.9 11 0.0002
GO:0031012 Extracellular matrix 5.5 10 0.012
GO, gene ontology.
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for 1 lM SIM versus 2.67  0.32 nmol/lg for the controls,
P < 0.001 for both) (Fig. 4B). However, the observed decreased min-
eralization by both doses of SIM was less severe compared to the
HCQ treatment. The combination of HCQ with either SIM doses signif-
icantly decreased the mineralization compared to either SIM dose
alone and is similar to the cells treated with HCQ only
(1.63  0.18 nmol/lg for 1 lM SIM versus 0.78  0.59 nmol/lg
for HCQ and 0.77  0.047 nmol/lg for 1 lM SIM + HCQ, P < 0.05
for both).
We also analysed gene expression for HMGCR (the enzyme inhib-
ited by SIM) in HCQ- and/or SIM-treated cells compared to control.
Although gene expression in SIM-treated cells was higher, the effect
was not significant. HCQ significantly increased HMGCR gene expres-
sion compared to controls (P < 0.05) (Fig. 4C). In addition, the com-
bination with SIM and HCQ resulted in a significantly increased
expression compared to either drug alone and to controls (P < 0.05
and P < 0.001, respectively). Furthermore, we analysed gene expres-
sion of ALP and DHCR7 in HCQ- and/or SIM-treated cells compared
to control. Expression of ALP was significantly increased by 0.2 lM
SIM compared to control (P < 0.001) (Fig. 4D). The combination of
SIM and HCQ was similar to HCQ alone, but significantly lower com-
pared to control (P < 0.001). Expression of DHCR7 was significantly
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increased by both HCQ and 1 lM SIM compared to control (P < 0.01
and P < 0.05, respectively) (Fig. 4E). The combination of SIM and
HCQ showed a synergistic effect leading to an increased DHCR7
expression compared to control (P < 0.001) (Fig. 4E).
Discussion
In the present study, we demonstrated that HCQ suppresses both
MSC-derived osteoblast differentiation and mineralization in vitro.
Although some of the pharmacodynamics of HCQ may apply to
specific biological processes in MSC-derived osteoblasts, we did not
come across studies reporting the direct effects of HCQ on MSC-
derived osteoblast differentiation or activity. Furthermore, we
demonstrated results of the microarray analysis comparing 5 lg/ml
HCQ-treated hMSCs to controls. Up-regulation of genes belonging to
the cholesterol biosynthesis pathway, lysosomal pathway and extra-
cellular matrix were the most significantly influenced processes by
5 lg/ml HCQ treatment. As SIM is a cholesterol synthesis inhibitor
and beneficial for osteoblast differentiation and mineralization, we
evaluated whether SIM could antagonize the negative effects of HCQ
and enhance MSC-derived osteoblast function simultaneously. Con-
trary to expected, SIM significantly decreased both MSC-derived
osteoblast differentiation and mineralization and the combination of
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SIM and HCQ yielded similar outcome compared to HCQ treatment
alone.
As patients with pSS, of which the majority is using HCQ, have a
higher BMD compared to healthy controls, we have been suggested
that HCQ is beneficial for either MSC-derived osteoblast differentia-
tion or mineralization [21]. However, our in vitro work showed that
both MSC-derived osteoblast differentiation (as measured by ALP
activity) and mineralization (as measured by calcium incorporation
and shown by mineralization stainings) are significantly decreased by
5 lg/ml HCQ treatment compared to controls.
We performed microarray analysis on both control and 5 lg/ml
HCQ-treated cells to assess potential mechanisms causing decreased
MSC-derived osteoblast differentiation and mineralization. We
showed that the up-regulation of genes involved in the cholesterol
metabolism pathway was the most significantly regulated process by
5 lg/ml HCQ compared to control samples. From this pathway, 10 of
24 enzymes were significantly up-regulated. Indeed, we confirmed
the up-regulation of this pathway by validating two of the involved
genes (ACAT2 and DHCR7) using RT-PCR. Based on this finding, we
speculate that either 1) HCQ has a direct positive regulatory effect on
cholesterol synthesis or 2) HCQ causes an intracellular cholesterol
depletion leading indirectly to increased cholesterol synthesis or
increased cholesterol uptake. The latter is in agreement with the
observed depletion of LDL cholesterol in vivo in patients that receive
HCQ [5, 6].
The role of cholesterol in MSC-derived osteoblast differentiation
has mainly been studied by the use of statins (e.g. SIM). SIM inhibits
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and thereby
blocks the synthesis of mevalonate and its downstream products
leading to decreased levels of cholesterol [32]. SIM activates Ras
signalling by inhibiting the synthesis of cholesterol leading to overex-
pression of BMP-2 through the PI3K/Akt/MAPK pathway. BMP-2 up-
regulates the expression of RUNX2, and phosphorylated RUNX2
stimulates a series of bone-specific gene transcriptions and promotes
the differentiation of osteoblasts [33, 34]. Indeed, both in vitro and
in vivo studies have reported the beneficial effects of statins on osteo-
blast differentiation and mineralization [35, 36]. Additionally, in vivo
studies showed that statins are a potential treatment for osteoporosis
[37, 38]. Based on these studies, we expected to find improved MSC-
derived osteoblast differentiation and/or mineralization and we specu-
lated that SIM may antagonize the negative effects of HCQ. However,
we found that both MSC-derived osteoblast differentiation and miner-
alization were significantly decreased in SIM-treated cells compared
to controls. Furthermore, MSC-derived osteoblast mineralization was
significantly decreased by the combination of SIM and HCQ compared
to cells treated with SIM only. A potential explanation might be that
HCQ leads, due to an unknown mechanism, to an intracellular choles-
terol depletion resulting in up-regulation of cholesterol synthesizing
enzymes as described earlier. Treatment with SIM would then block
this compensatory mechanism of the cell which may lead to
decreased MSC-derived osteoblast development and activity. Indeed,
gene expression of HMGCR is significantly increased in HCQ and
SIM-treated cells and it seems that both drugs have synergistic
effects supporting our hypothesis. It remains unclear, however, why
SIM did not have beneficial effects on MSC-derived osteoblasts in our
experiments. Another possible explanation might be the use of
hMSCs, as many studies showing beneficial effects of SIM used dif-
ferent type of cell lines [39]. A third explanation might be that 1 lM
SIM has still toxic effects leading to impaired MSC-derived osteoblast
activity without leading to apoptosis. Despite using a dose–response
experiment for SIM and following the methods as described in other
papers, we could not confirm previously reported beneficial effects of
SIM.
We showed a highly significant up-regulation of the endosomal/
lysosomal system by HCQ compared to the controls in our microarray
analysis. Surprisingly, the most up-regulated gene was CTSK, a lyso-
somal protease, which is predominantly known to be involved in bone
resorption by osteoclasts [40, 41]. The role of CTSK in osteoblasts is
less well understood, and the majority of these studies are performed
in mice. Mandelin et al. reported that osteoblast-like cells indeed pro-
duce CTSK mRNA and release processed cathepsin K into culture
media in vitro [42]. A study performed in a Ctsk knockout mouse
showed a significantly increased number of osteoblasts in the fracture
callus with associated increased callus mineral density and strength
compared to wild-type mice [43]. As we demonstrated a significantly
decreased MSC-derived osteoblast differentiation and mineralization
and a significant up-regulation of CTSK expression in HCQ-treated
MSC-derived osteoblasts, a direct relation between CTSK up-regula-
tion and the observed phenotype is too premature at this stage.
According to literature, HCQ has been associated with increased
LMP leading to apoptosis [20]. LMP is caused by loss of cholesterol
in the lysosomal membrane leading to the release of cathepsins and
protons from the lysosomal lumen into the cytosol where they partici-
pate in apoptosis signalling [44]. This may lead to the observed up-
regulation of CTSK gene expression in order to compensate for the
loss. Additionally, cholesterol is identified as a stabilizer of the lysoso-
mal membrane and may therefore counter LMP.
Finally, the decreased mineralization may be caused by HCQ-
induced alteration in the extracellular matrix (ECM) gene expression
profile as this was one of the regulated GO terms following HCQ treat-
ment. Eijken et al. reported that activin signalling in human osteo-
blasts changes the expression of a specific range of ECM proteins
prior to the onset of mineralization, leading to a matrix composition
with reduced or no mineralizing capacity [28]. In agreement with this,
we found similar ECM gene expression alterations due to HCQ treat-
ment compared to controls in our microarray experiment (down-reg-
ulation of ALPL and CLEC3B; up-regulation of POSTN, MMP7 and
MMP15). In addition, we showed that staining for yet another ECM
protein, vinculin, was significantly decreased in HCQ-treated cells
compared to controls. Therefore, we speculate that HCQ leads to
reduced cell-surface attachment and altered ECM composition leading
to decreased matrix mineralization.
Based on these findings, our final hypothesis is that HCQ ‘attacks’
the lysosomal membrane by removing cholesterol leading to
decreased osteoblast differentiation and mineralization. As a compen-
satory mechanism, both the cholesterol synthesis pathway and the
lysosomal pathway are up-regulated in an attempt to restore osteo-
blast function. In addition, HCQ may also affect ECM composition
leading to decreased cell attachment, differentiation and matrix min-
eralization. The discrepancy between high BMD and decreased MSC-
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derived osteoblast function due to HCQ treatment might be caused by
systemic factors that stimulate bone formation and/or systemic or
local factors that reduce bone resorption which is lacking in cell cul-
tures. In fact, we have shown that HCQ strongly suppresses bone
resorption in vitro and in vivo and in women with a high bone turn-
over state, this may lead to a net increase in bone mass [25].
The strength of this study is that we performed an unbiased evalu-
ation of potential mechanisms of action for the observed decreased
MSC-derived osteoblast differentiation and mineralization using
microarrays. Additionally, genetic data from the microarray were
translated into functional experiments, but the precise mechanism
remains elusive.
In conclusion, we demonstrated that HCQ suppresses MSC-
derived osteoblast differentiation and mineralization in vitro. Fur-
thermore, we reported results of our microarray analysis showing
significant up-regulation of the cholesterol biosynthesis and
lysosomal pathway. Surprisingly, treatment with SIM and HCQ also
resulted in decreased MSC-derived osteoblast differentiation and
mineralization. A potential mechanism could be HCQ-induced LMP
leading to decreased MSC-derived osteoblast development and
activity.
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